Randomized phase III trial comparing 16 to 18 weeks of neoadjuvant exemestane (25 mg daily), letrozole (2.5 mg), or anastrozole (1 mg) in postmenopausal women with clinical stage II and III estrogen receptor positive breast cancer

eagle-i ID

Resource Type

Properties

1. ClinicalTrials.gov url

   http://www.clinicaltrials.gov/ct2/show/NCT00265759?term=ACOSOG-Z1031&rank=1

2. Intervention

   Anastrozole

3. Intervention

   Exemestane

4. Intervention

   Letrozole

5. Additional Topic(s)

   Antineoplastic combined chemotherapy protocols

6. Resource Description

   It is not yet known whether exemestane, letrozole, or anastrozole is more effective in treating breast cancer. This randomized phase III trial is studying exemestane, letrozole, and anastrozole to compare how well they work in treating postmenopausal women who are undergoing surgery for stage II or stage III breast cancer.

7. Contact

   Berenberg, Jeffrey

8. PI

   Berenberg, Jeffrey

9. Topic

   breast cancer

10. Study Population

    Females with measurable disease, no inflammatory breast cancer, estrogen receptor positive tumor, and no previous radiation therapy, hormone therapy, or chemotherapy for invasive breast cancer.

11. Website(s)

    http://www.cancer.gov/clinicaltrials/featured/trials/acosog-z1032

12. Website(s)

    http://www.cancer.gov/clinicaltrials/search/view?cdrid=456382&version=healthprofessional

13. Funded by

    Cancer Trials Support Unit

14. Phase

    Phase 2 clinical trial

15. Performed by

    Clinical Protocol & Data Management Shared Resource